Betsy Martin

Betsy Martin is a Scientist II in Target Biology at Lyterian Therapeutics, bringing extensive experience in discovery biology research from BridgeBio, where Martin served as Lead Scientist and managed a team to develop a small molecule inhibitor for Autosomal dominant polycystic kidney disease. At BridgeBio, Martin also led an Antisense Oligonucleotide program for diffuse intrinsic pontine glioma, establishing key cellular assays for target knockdown efficacy. Prior to that, Martin was a Graduate Student Researcher at UCSF, focusing on DNA cytosine modifications in mouse embryonic stem cells, and held a Lab Manager position at UC Irvine. Martin's academic background includes a PhD in Biochemistry and Molecular Biology from UCSF and a Bachelor's degree in Biology from Claremont McKenna College.